Chemotherapy for urothelial cancer of the bladder - Update 2012;Chemotherapie des Urothelkarzinoms der Harnblase - Update 2012

Aktuelle Urologie

Volumn 43, Issue 6, 2012, Pages 412-419

  Niegisch, G ^a   Lorch, A ^a   Albers, P ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

chemotherapy; prognostic factors; targeted therapy; urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BLADDER TUMOR; CANCER STAGING; CYSTECTOMY; HUMAN; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; SURVIVAL; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84870062218     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0032-1327699     Document Type: Article

References (81)

1. Robert-Koch-Institut Daten zur Krebsinzidenz und -mortalität in Deutschland. In Krebs in Deutschland 2010 www.rki.de
2. Sylvester R. J., van der Meijden A. P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol: 2006; 49 465 466 discussion 467-475
3. Kiemeney L. A., Witjes J. A., Verbeek A. L. et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer: 1993; 67 806 812 (Pubitemid 23101564)
4. Rogers C. G., Palapattu G. S., Shariat S. F. et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol: 2006; 175 2048 2053 discussion 2053 (Pubitemid 43668580)
5. Hautmann R. E., Gschwend J. E., de Petriconi R. C. et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol: 2006; 176 486 492 discussion 482-491 (Pubitemid 43927871)
6. Madersbacher S., Hochreiter W., Burkhard F. et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol: 2003; 21 690 696 (Pubitemid 46621904)
7. von der Maase H., Sengelov L., Roberts J. T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol: 2005; 23 4602 4608 (Pubitemid 46224062)
8. Winquist E., Kirchner T. S., Segal R. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol: 2004; 171 561 569 (Pubitemid 38090430)
9. ABC-Meta-analysis-Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol: 2005; 48 202 205 discussion 205-206
10. ABC-Meta-analysis-Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet: 2003; 361 1927 1934
11. Sherif A., Rintala E., Mestad O. et al. Neoadjuvant cisplatin- methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2. Scand J Urol Nephrol: 2002; 36 419 425 (Pubitemid 36169500)
12. Grossman H. B., Natale R. B., Tangen C. M. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med: 2003; 349 859 866 (Pubitemid 37025405)
13. Malmstrom P. U., Rintala E., Wahlqvist R. et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol: 1996; 155 1903 1906 (Pubitemid 26144081)
14. Inernational-Collaboration-of-Trialists Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet: 1999; 354 533 540
15. Griffiths G., Hall R., Sylvester R. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol: 2011; 29 2171 2177
16. Sternberg C. N., de Mulder P. H., Schornagel J. H. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol: 2001; 19 2638 2646 (Pubitemid 32441368)
17. von der Maase H., Hansen S. W., Roberts J. T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol: 2000; 18 3068 3077
18. Canter D., Viterbo R., Kutikov A. et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology: 2011; 77 160 165
19. Raj G. V., Karavadia S., Schlomer B. et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer: 2011; 117 276 282
20. Scosyrev E., Messing E. M., van Wijngaarden E. et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer: 2012; 118 72 81
21. Yeshchina O., Badalato G. M., Wosnitzer M. S. et al. Relative efficacy of perioperative gemcitabine and Cisplatin versus methotrexate, vinblastine, adriamycin, and Cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology: 2012; 79 384 390
22. Dash A., JAt Pettus, Herr H. W. et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer: 2008; 113 2471 2477
23. Koga F., Kihara K., Fujii Y. et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int: 2009; 104 189 194
24. Svatek R. S., Shariat S. F., Novara G. et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int: 2011
25. Rajesh A., Sokhi H. K., Fung R. et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol: 2011; 66 1140 1145
26. Tekes A., Kamel I., Imam K. et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol: 2005; 184 121 127 (Pubitemid 40040915)
27. Baltaci S., Resorlu B., Yagci C. et al. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int: 2008; 81 399 402
28. Lodde M., Lacombe L., Friede J. et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int: 2010; 106 658 663
29. Picchio M., Treiber U., Beer A. J. et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med: 2006; 47 938 944 (Pubitemid 46939945)
30. Saokar A., Islam T., Jantsch M. et al. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging: 2010; 34 361 366
31. Apolo A. B., Riches J., Schoder H. et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol: 2010; 28 3973 3978
32. Swinnen G., Maes A., Pottel H. et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol: 2010; 57 641 647
33. Smith S. C., Baras A. S., Dancik G. et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol: 2011; 12 137 143
34. [Anonym] Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol: 2005; 48 189 199 discussion 199-201
35. Wiesner C., Salzer A., Thomas C. et al. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int: 2009; 104 331 335
36. Bruins H. M., Huang G. J., Cai J. et al. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol: 2009; 182 2182 2187
37. Lehmann J., Retz M., Wiemers C. et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol: 2005; 23 4963 4974 (Pubitemid 46224002)
38. Paz-Ares L. G., Solsona E., Esteban E. et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Chicago ASCO: 2010
39. Cognetti F., Ruggeri E. M., Felici A. et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol: 2012; 23 695 700
40. Svatek R. S., Shariat S. F., Lasky R. E. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res: 2010; 16 4461 4467
41. Stadler W. M., Lerner S. P., Groshen S. et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol: 2011; 29 3443 3449
42. Ghoneim M. A., Abdel-Latif M., el-Mekresh M. et al. Radical cystectomy for carcinoma of the bladder: 2720 consecutive cases 5 years later. J Urol: 2008; 180 121 127
43. Kassouf W., Svatek R. S., Shariat S. F. et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol: 2011
44. Lehmann J., Suttmann H., Albers P. et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol: 2009; 55 1293 1299
45. Roberts J. T., von der Maase H., Sengelov L. et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol: 2006; 17 05 v118 v122 (Pubitemid 43985220)
46. Bellmunt J., von der Maase H., Mead G. M. et al. Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. J Clin Oncol: 2012
47. Hahn N. M., Stadler W. M., Zon R. T. et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol: 2011; 29 1525 1530
48. Philips G. K., Halabi S., Sanford B. L. et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol: 2009; 20 1074 1079
49. Hussain M. H., MacVicar G. R., Petrylak D. P. et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol: 2007; 25 2218 2224 (Pubitemid 46954646)
50. Krege S., Rexer H., vom Dorp F. et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). Chicago ASCO: 2010
51. Galsky M. D., Sonpavde G., Hellerstedt B. A. et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). Chicago ASCO: 2010
52. Sridhar S. S., Winquist E., Eisen A. et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs: 2011; 29 1045 1049
53. Bellmunt J., Theodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol: 2009; 27 4454 4461
54. Sweeney C. J., Williams S. D., Finch D. E. et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer: 1999; 86 514 518 (Pubitemid 29347415)
55. Soga N., Onishi T., Arima K. et al. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol: 2007; 14 828 832 (Pubitemid 47313275)
56. Lin C. C., Hsu C. H., Huang C. Y. et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs: 2007; 18 487 491
57. Krege S., Rembrink V., Borgermann C. et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol: 2001; 165 67 71
58. Albers P., Park S. I., Niegisch G. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol: 2011; 22 288 294
59. Sternberg C. N., Calabro F., Pizzocaro G. et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer: 2001; 92 2993 2998 (Pubitemid 33136193)
60. Fechner G., Siener R., Reimann M. et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract: 2006; 60 27 31 (Pubitemid 43732573)
61. Kanai K., Kikuchi E., Ohigashi T. et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol: 2008; 13 510 514
62. Suyama T., Ueda T., Fukasawa S. et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol: 2009; 39 244 250
63. Wulfing C., Machiels J. P., Richel D. J. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer: 2009; 115 2881 2890
64. Petrylak D. P., Tangen C. M., Van Veldhuizen P. J. Jr et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int: 2010; 105 317 321
65. Dreicer R., Li H., Stein M. et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer: 2009; 115 4090 4095
66. Gallagher D. J., Milowsky M. I., Gerst S. R. et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol: 2010; 28 1373 1379
67. Necchi A., Nicolai N., Ortega C. et al. Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC). Chicago ASCO: 2012
68. Milowsky M. I., Regazzi A. M., Garcia-Grossman I. R. et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Chicago ASCO: 2011
69. Seront E., Rottey S., Sautois B. et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol: 2012
70. Niegisch G., Retz M., Thalgott M. K. et al. Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09). Chicago ASCO: 2012
71. Wong Y. N., Litwin S., Vaughn D. et al. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. J Clin Oncol: 2012
72. Dash A., Galsky M. D., Vickers A. J. et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer: 2006; 107 506 513 (Pubitemid 44107210)
73. Balducci L., Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park): 2000; 14 221 227
74. De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol: 2012; 30 191 199
75. Bajorin D. F., Dodd P. M., Mazumdar M. et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol: 1999; 17 3173 3181 (Pubitemid 29470648)
76. Bellmunt J., Albanell J., Paz-Ares L. et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer: 2002; 95 751 757 (Pubitemid 34839666)
77. Bellmunt J., Choueiri T. K., Fougeray R. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol: 2010; 28 1850 1855
78. Niegisch G., Fimmers R., Siener R. et al. Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99). Eur Urol: 2011; 60 1087 1096
79. Bellmunt J., Paz-Ares L., Cuello M. et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol: 2007; 18 522 528 (Pubitemid 46359633)
80. Als A. B., Dyrskjot L., von der Maase H. et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res: 2007; 13 4407 4414 (Pubitemid 47219707)
81. Gallagher D., Joseph V., Garcia-Grossman I. R. et al. Germline single-nucleotide polymorphisms (SNPs) associated with response of urothelial carcinoma (UC) to platinum-based therapy: The role of the host. Chicago ASCO: 2011